Neuropathix Inc - ESG Rating & Company Profile powered by AI
The Disclosure rating covers 17 United Nations SDGs including: 'Zero Hunger', 'Sustainable Cities & Communities' and 'Life below Water'. This ESG assessment for Neuropathix Inc represents its reporting of the UN SDGs. The webpage is a zero-cost Environmental, Social and Governance analysis for Neuropathix Inc.
Neuropathix Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.0; made up of an environmental score of 0.0, social score of 0.0 and governance score of 0.0.
0.0
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1967 | Hospira Inc | 0.3 | Low |
1967 | PRA Health Sciences Inc | 0.3 | Low |
1970 | Neuropathix Inc | 0.0 | Low |
1970 | CSPC Innovation Pharmaceutical Co Ltd | 0.0 | Low |
1970 | CTC Bio Inc | 0.0 | Low |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Neuropathix Inc have an accelerator or VC vehicle to help deliver innovation?
Does Neuropathix Inc disclose current and historical energy intensity?
Does Neuropathix Inc report the average age of the workforce?
Does Neuropathix Inc reference operational or capital allocation in relation to climate change?
Does Neuropathix Inc disclose its ethnicity pay gap?
Does Neuropathix Inc disclose cybersecurity risks?
Does Neuropathix Inc offer flexible work?
Does Neuropathix Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Neuropathix Inc disclose the number of employees in R&D functions?
Does Neuropathix Inc conduct supply chain audits?
Does Neuropathix Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Neuropathix Inc conduct 360 degree staff reviews?
Does Neuropathix Inc disclose the individual responsible for D&I?
Does Neuropathix Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Neuropathix Inc disclose current and / or historical scope 2 emissions?
Does Neuropathix Inc disclose water use targets?
Does Neuropathix Inc have careers partnerships with academic institutions?
Did Neuropathix Inc have a product recall in the last two years?
Does Neuropathix Inc disclose incidents of discrimination?
Does Neuropathix Inc allow for Work Councils/Collective Agreements to be formed?
Has Neuropathix Inc issued a profit warning in the past 24 months?
Does Neuropathix Inc disclose parental leave metrics?
Does Neuropathix Inc disclose climate scenario or pathway analysis?
Does Neuropathix Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Neuropathix Inc disclose the pay ratio of women to men?
Does Neuropathix Inc support suppliers with sustainability related research and development?
Does Neuropathix Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Neuropathix Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Neuropathix Inc involved in embryonic stem cell research?
Does Neuropathix Inc disclose GHG and Air Emissions intensity?
Does Neuropathix Inc disclose its waste policy?
Does Neuropathix Inc report according to TCFD requirements?
Does Neuropathix Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Neuropathix Inc disclose energy use targets?
Does Neuropathix Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Neuropathix Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Neuropathix Inc
These potential risks are based on the size, segment and geographies of the company.
Neuropathix, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics from its proprietary synthetic cannabinoid derivatives platform. It engages in the research and development of chemical entities, such as KLS-13019, KLS-13023, and KLS-13022, as well as its related molecules; and synthetic cannabidiol therapeutics through pre-clinical drug discovery and development processes for use in the disease indications of chemotherapy induced peripheral neuropathy, overt hepatic encephalopathy, mild traumatic brain injury, and chronic traumatic encephalopathy. The company was formerly known as Kannalife, Inc. and changed its name to Neuropathix, Inc. in November 2020. Neuropathix, Inc. was founded in 2010 and is based in Doylestown, Pennsylvania.